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Abstract: Cancer is considered the second leading cause of death worldwide and in 2018 it was
responsible for approximately 9.6 million deaths. Globally, about one in six deaths are caused by
cancer. A strong correlation was found between diabetes mellitus and carcinogenesis with the most
evident correlation was with type 2 diabetes mellitus (T2DM). Research has proven that elevated
blood glucose levels take part in cell proliferation and cancer cell progression. However, limited
studies were conducted to evaluate the efficiency of conventional therapies in diabetic cancer patients.
In this review, the correlation between cancer and diabetes will be discussed and the mechanisms by
which the two diseases interact with each other, as well as the therapeutics challenges in treating
patients with diabetes and cancer with possible solutions to overcome these challenges. Natural
products targeting both diseases were discussed with detailed mechanisms of action. This review will
provide a solid base for researchers and physicians to test natural products as adjuvant alternative
therapies to treat cancer in diabetic patients.
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1. Introduction
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Diabetes mellitus is a class of metabolic disorders characterized by prolonged periods of hyperglycemia. According to the World Health Organization (WHO), in the year
2014, 422 million people worldwide suffered from diabetes, and 1.6 million deaths were
directly related to diabetes in the year 2016. Moreover, these statistics have been rising
slowly over the last few decades [1]. Diabetes mellitus (DM) is displayed as either type
1 diabetes mellitus (result from total insulin deficiency due to beta-cell death follow an
autoimmune disease) or type 2 Diabetes Mellitus (predominantly resulting from insulin
resistance, rendering target cells unable to effectively respond to insulin and so unable
to utilize blood glucose for energy). It is well known that diabetes mellitus increases the
risk of developing a variety of severe life-threatening health complications, resulting from
the disruption and impairment in the function of several organs (kidneys, hearts, skin,
blood vessels, or nerves), leading to both microvascular and macrovascular complications
which include nephropathy, diabetic retinopathy, and neuropathy, as well as atherosclerosis, hypertension, and stroke. These diabetic vascular complications are responsible
for the majority of mortality in diabetic patients [2]. In addition to these complications,
elevated blood glucose levels have been shown to stimulate cancer cell proliferation and
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progression [3]. Studies have shown a strong correlation between diabetes mellitus and
carcinogenesis and the most evident correlation is reported with type 2 diabetes mellitus
(T2DM). Nevertheless, In type 1 diabetes mellitus (T1DM), the risk of carcinogenesis has
also been identified but is less evident compared to that with T2DM [4]. However, in
both types of diabetes mellitus cancer incidence tends to be increased [5]. Cancer is the
second leading cause of death worldwide and in the year 2018, approximately 9.6 million
deaths were attributed to cancer, and nearly one in six deaths around the world are caused
by cancer [6]. Both diabetes and cancer have a dramatic detrimental effect on both the
mortality rate and the quality of life, and the simultaneous rise in incidence rates of both
diseases has encouraged the research community to search into a possible correlation in
terms of pathophysiological pathways and/or the common climate [7]. Hyperglycemia
causes epigenetic alterations by several mechanisms including DNA methylation and chromatin remodeling, resulting in abnormal gene expression. Moreover, in cancer, abnormal
gene expression causes tumor growth by increasing the metastases, proliferation, and
chemoresistance of cancer cells [8]. The proliferation of cancer cells which is induced by
hyperglycemia/diabetes occurs indirectly by mediating the following processes (1) insulin
and insulin-like growth factor 1 (IGF-1), (2) secretion of leptin/adiponectin, (3) inflammatory responses, (4) production of reactive oxygen species (ROS; oxidative stress) and
(5) immune abnormalities (platelet activation) [9]. In addition to a direct correlation between impaired glucose tolerance/diabetes and the initiation of cancer, proliferation and
invasiveness may occur due to hyperglycemia [10]. Many epidemiological reports have
shown that diabetes is positively associated with several types of cancers including breast,
colorectal, endometrial, liver and pancreatic cancers. On the other hand, a decreased
prevalence of prostate cancer has been observed in diabetic patients [11]. Ben et al. found a
significant association between DM and pancreatic with an inverse correlation between the
duration of DM and the occurrence of pancreatic cancer in both sexes, thus observing the
greatest risk of developing pancreatic cancer in patients with a duration of DM shorter than
1 year after diagnosis [12]. Similar findings were observed in another study [13]. Cancer
risk in diabetic patients is 20% higher based on a meta-analysis of 20 studies [14]. The
analysis of data obtained by Hulda Hrund Bjornsdottir et al. on 450,000 people with type 2
diabetes and more than 2 million people without diabetes in Sweden between 1998 and
2014 was unable to show a cause-and-effect relationship. Nevertheless, people with blood
sugar disease were observed to have a higher risk of developing several types of cancer
including a 231% higher risk of hepatocellular cancer, a 119% higher risk of pancreatic
cancer, and a 78% higher risk of uterine cancer compared to those without type 2 diabetes.
Additionally, people with diabetes had an elevated risk of kidney cancer (45% higher),
stomach cancer (21% higher), cancer of the gallbladder and bile duct (32% higher), and
penile cancer (56% higher). Moreover, the incidence of colorectal cancer and bladder cancer
was also 20% higher, while the breast cancer risk was 5% higher [15]. Besides the increased
risk of cancer by hyperglycemia/diabetes, several meta-analysis studies have also linked
diabetes with a higher incidence of poor post-treatment prognosis in diabetic cancer subjects [16]. In addition, the effect of hyperglycemia on breast cancer chemotherapy resistance
have been shown in recent studies [17]. Although epidemiological studies have shown
that cancer mortality in diabetic patients is relatively increased, it is still unclear if this is a
consequence of hyperglycemia and hyperinsulinemia (growth-promoting effect on cancer
cells), poor health conditions attributable to diabetes comorbidity, or a combination of all
these factors [18]. There is strong evidence that cancer patients with diabetes are treated
less aggressively or are expected to be less likely treated with modified anti-cancer therapy
than non-diabetic cancer patients [19]. Some anti-diabetic drugs, such as metformin, have
been shown to reduce the incidence of cancer in diabetes patients, enhance the efficacy of
anti-cancer drugs and also has shown favorable survival in cancer patients [16]. This review
presents a detailed discussion of the major metabolic changes in cancer cells that maintain
their development. Furthermore, since diabetes is a metabolic syndrome we will discuss
the metabolic linkage between diabetes and cancer. We also will describe therapeutic
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challenges facing treating diabetic patients with cancer and suggested therapies. Finally,
we will explore various natural products that have the capacity to target both diseases and
the mechanisms of action on both diseases.
2. Cancer Altered Metabolism
Generally, cancer cells have the ability to proliferate from one abnormal cell to more
than 109 cells (the total number of cells ~1 cm in diameter in a tumor) if suitable conditions are available [20]. Tumor cells will modify their metabolism to guarantee survival,
overpower host immune attack, and maintain the proliferative capacity to induce their
lethal effects and sustain survival [21]. Cancer cells undergo physiological adaptations
to preserve their survival under many stressful conditions, such as hypoxia and food
hunger in order to fulfill their massive growth requirements. Such metabolic modifications
generate abnormal metabolic events when compared to normal cells. This reprogrammed
metabolism is seen as a cancer signature, as many metabolic modifications are predominant
in several other types of cancers [22]. Similar to normal cells, cancer cells also have to
produce ATP to maintain both daughter cells formed through division, rely on metabolic intermediates or biosynthesis by-products and, most critically, to compete with the oxidizing
effects to mitigate the impact of reactive oxygen species (ROS). These altered metabolic and
bioenergetic mechanisms, significantly elevated biosynthesis and redox equilibrium, are
crucial to cancer progression [23]. Therefore, proliferating cells need to obtain high amounts
of lipids, nucleotides, and amino acids. Through using by-products and derivatives of
the TCA (tricarboxylic acid) cycle, cells can generate this biomass [24]. It would appear
that fulfilling all these requirements would require a significant boost in glucose uptake in
tumors. The high glucose consumption in many, but not all, tumors have been verified by
PET (positron emission tomography) imaging and glucose consumption rates beyond the
levels that can be easily explained by energy or metabolite requirements [25]. Moreover,
the utilization of glutamine meets a symmetrical pattern of excessive consumption [26]. It
is believed that cancer metabolism could be described as upregulation of the metabolism
of both glucose and glutamine for the production of energy.
2.1. Glucose
Glucose is the principal source of cellular energy and in the presence of oxygen, it
is metabolized to pyruvate through glycolysis, which is transported to the mitochondria,
where it is oxidatively metabolized into CO2 in the tricarboxylic acid (TCA) cycle and the
oxidative phosphorylation via electron transport chain (ETC) to produce high amounts of
energy (for each molecule of glucose about 32 to 34 molecules of ATP are produced) [27].
Cells may also undergo anaerobic glycolysis without oxygen, i.e., fermentation, diverting
the resulting pyruvate molecules towards lactate production which is less effective in
ATP production than the TCA cycle coupled with oxidative phosphorylation. Similarly,
cancer cells primarily metabolize glucose, but in contrast to normal cells and in spite of the
presence of oxygen, glycolysis produces lactate leading to the generation of two ATP per
molecule of glucose. Consequently, cancer cells need a high glucose utilization efficiency so
as to fulfill their energy and anabolic requirements, Otto Heinrich Warburg in 1920 found
that even in ample oxygen, glycolysis was improved in cancer cells. However, glycolysis
was commonly known to increase under anaerobic conditions [28]. Despite deficiency in
oxygen, increased glycolysis in cancer cells seemed to be a new phenomenon and was
referred to as aerobic glycolysis or the “Warburg effect” [29]. Consequently, the high quantity of glucose catabolism into lactate has been the most widespread metabolic phenotype
detected in cancer cells, contributing to the deposition of lactate by-products within the
tumor’s microenvironment [20]. Currently, it is obvious that cancer cells experience aerobic
glycolysis due to oncogene stimulation, tumor suppressor genes inhibition, and activation
of phosphatidylinositol 3-kinase (PI3K) pathway, and that one benefit of high glycolytic
frequencies is the availability of anabolic pathway substrates [30]. The expression of glucose transporters in tumor cells is deregulated by some oncogenes (such as Myc oncogene),
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high glycolytic frequencies is the availability of anabolic pathway substrates [30]. The expression of glucose transporters in tumor cells is deregulated by some oncogenes (such as
Myc oncogene), resulting in over-expression of these transporters, especially GLUT1 and
resulting in over-expression of these transporters, especially GLUT1 and GLUT3 [31]. The
GLUT3 [31]. The idea that cancer cells utilize glucose as a fuel is explained as follows;
idea that cancer cells utilize glucose as a fuel is explained as follows; glucose begins to be
glucose begins to be processed in the cytosol, and is converted to glucose-6-phosphate
processed in the cytosol, and is converted to glucose-6-phosphate (G6P) by Hexokinase
(G6P) by Hexokinase (HK). Glucose-6-phosphate (G6P) is the splitting point from glycol(HK). Glucose-6-phosphate (G6P) is the splitting point from glycolysis to the pentose
ysis to the pentose phosphate pathway oxidative branch (PPP) that produces the ribose
phosphate pathway oxidative branch (PPP) that produces the ribose group needed for
group needed for nucleotide synthesis (RNA and DNA synthesis). This pathway is imnucleotide synthesis (RNA and DNA synthesis). This pathway is important in order to
portant in order to enable cancer cells to fulfill their anabolic demands and survive oxidaenable cancer cells to fulfill their anabolic demands and survive oxidative and nutritional
tive and nutritional stress [32]. In this pathway, glucose-6-phosphate (G6P) is broken up
stress [32]. In this pathway, glucose-6-phosphate (G6P) is broken up into three-carbon
into three-carbon compounds, 3-phosphoglyceraldehyde, which is the main point for the
compounds, 3-phosphoglyceraldehyde, which is the main point for the non-essential amino
non-essential amino acid serine synthesis. Phosphoenolpyruvate (PEP) is also formed by
acid serine synthesis. Phosphoenolpyruvate (PEP) is also formed by glycolysis and end up
glycolysis and end up producing two pyruvate molecules [20]. The glycolytic enzyme pyproducing two pyruvate molecules [20]. The glycolytic enzyme pyruvate kinase enzyme
ruvate
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Figure 1. Cancer altered metabolism. G6P, glucose-6-phosphate; LDH, lactate dehydrogenase
enzyme; α-KG, alpha-ketoglutarate. Created using Biorender software.
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3. Diabetes Relationship with Metabolic Syndrome (MetS)
A metabolic syndrome was described for the first time by Reavan in 1988, in which
he suggested that it was an essential feature in developing Chronic Heart disease (CHD)
and Diabetes Mellitus type II (DMTII), mostly through insulin resistance [40]. Afterwards,
established criteria for metabolic syndrome clinical identification have been emerged
by NCEP-ATP III (the National Cholesterol Education Program/Adult Treatment Panel
III) [41,42], WHO (the World Health Organization), IDF (the International Diabetes Federation) [43], and AACE (the American Association Clinical Endocrinologists) [44] (Shown in
Table 1).
According to NHANES III (the 3rd National Health and Nutrition Examination Survey) criteria, almost 47 million people have metabolic syndrome [45]. Moreover, more
than 2 in 10 cancers in the UK are thought to be related to metabolic syndrome [46]. The
risk of developing metabolic syndrome is increased with age, and it has been estimated
that, in the age group of over 50 years, more than 40% in the United States and nearly
30% in Europe of this age group have metabolic syndrome [47,48]. Recently, Esposito et al.
using a meta-analysis, examined 38,940 patients with metabolic syndrome and cancer, and
the study results showed that metabolic syndrome increases the risk of several cancers
including colorectal, pancreas, and liver cancers. However, the reported results showed
differences between genders. In men, the metabolic syndrome was strongly linked with
both liver and colorectal cancers but weakly linked with bladder cancer. On the other hand
in women, the metabolic syndrome was linked with endometrial, pancreas, breast (especially in postmenopausal women), colorectal, and ovary cancers [49]. Table 1 summarizes
various definition of metabolic syndrome.
Table 1. Various definitions of metabolic syndrome.
NCEP/ATP III

WHO 1999

IDF

Risk Factors

(3 of 5 criteria necessary)
[41,42]

(impaired glucose regulation
or hyperinsulinemia and 2 or
more criteria necessary) A

(increased waist
circumference plus any 2 of
other 4 criteria) [50]

Fasting glucose

≥110 mg/dL

≥110 mg/dL

≥110 mg/dL

Prandial glucose

>140 mg/dL

Hyperinsulinemia

Fasting serum insulin: third
quartile for the control group

Hypertriglyceridemia B
Low HDL-C
Men
Women
Abdominal obesity
Men
Women
Hypertension B
Micro-albuminuria

≥150 mg/dL

≥150 mg/dL

≥150 mg/dL

<40 mg/dL
<50 mg/dL

<35 mg/dL
<39 mg/dL

<40 mg/dL
<50 mg/dL

>102 cm
>88 cm

waist: hip ratio
>0.9 in
>0.85 in

≥94 cm
≥80 cm

≥130/≥85 mm Hg

≥140/≥90 mm Hg

≥130/≥85 mm

≥20 µg/min

A

World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO
consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999. B Considered
positive criteria if a person is on medications for lipids, hypertension, or hyperglycemia regardless of value. Abbreviations: NCEP/ATP
III, National Cholesterol Education Program/Adult Treatment Panel III; WHO, World Health Organization; IDF, International Diabetes
Federation; HDL, high-density lipoprotein.

Insulin is considered the primary anabolic hormone and has an essential function
in stimulating cell proliferation [51]. In healthy individuals, the blood glucose level is
tightly controlled by both insulin release and insulin-mediated glucose uptake in the tissues [52]. On the other hand, when the response of the normal cells to insulin is weakened,
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a condition called insulin resistance is produced. As a result, the pancreas β-cells respond
to this condition by increasing the secretion of insulin into the circulation, causing hyperinsulinemia (High insulin concentration in the blood] in order to maintain a normal
blood glucose level [53]. Insulin resistance creates a favorable environment for neoplastic
tissue survival and cancer cell development [54–56], this could be explained through the
abnormally elevated levels of growth factors, ROS (Reactive Oxygen Species), adipokines,
and proinflammatory cytokines that are associated with this condition.
The primary mechanism for many features of metabolic syndrome is suggested to be
insulin resistance or hyperinsulinemia. Studies have shown that chronic hyperinsulinemia
is also associated with several cancer types such as colorectal, pancreatic, endometrial,
and breast cancers [57]. Hyperinsulinemia reduces the production of IGFBP-I and -II
(Insulin-like growth factor binding protein) thus increasing IGF-I (Insulin-like growth
factor) level in the blood, and promoting tumor development by changing the cellular
environment [58]. In addition, hyperinsulinemia inhibits the synthesis of SHBG [Sex
hormone-binding Globulin] leading to increased free sex hormone levels thus promoting
sex hormone-dependent cancers such as endometrial, breast and prostate cancers [58].
Metabolic syndrome is also characterized by hyperglycemia [29], however, this does not
mean that every diabetic patient has MetS since it is about three times more common than
diabetes [59]. The results of a study done by Flood et al. to investigate the relationship
between insulin, fasting glucose, and colorectal adenomas recurrence risk, showed that the
risk for colorectal recurrence is higher in patients with elevated insulin and glucose [60].
A relationship between insulin resistance or hyperinsulinemia with different types
of epithelial cancers has been shown by several population-based studies. Initial studies
on prostate cancers showed a link with plasma IGF-I concentration [61]. On the other
hand, different studies have confirmed that both elevated IGF-I and insulin levels are
associated with prostate cancer risk, prospectively [62–64]. Moreover, a link has been
shown between hyperinsulinemia and breast cancer risk (measured by fasting C-peptide
concentration) mainly in postmenopausal breast cancer [65] and also with endometrial
cancer risk independent of estradiol [66].
4. Metabolic Link between Diabetes and Cancer
The potential metabolic links between DM and cancer development are hyperinsulinemia, hyperglycemia, and chronic inflammation due to fat imbalanced metabolism.
4.1. Hyperinsulinemia
The role of insulin’s in carcinogenesis is mainly influenced by insulin receptor (IR),
Insulin-like Growth Factor (IGF), and Insulin-like Growth Factor Receptor (IGF-R) [4].
In diverse human malignancies, it was found that there is overexpression in the IR, the
fetal isoform IR-A in particular, and in the IGF-R [67,68]. Moreover, tumor cells can
produce hybrid forms of insulin and IGF-1 receptors that can either be activated by insulin,
IGF-1, and/or IGF-2 [69]. Insulin receptor (IR) is composed of two α-subunits and two
β-subunits, expresses the activity of tyrosine kinase and is strongly activated by insulin,
while both IGF-1 and IGF-2 possess weaker activation [70,71]. The biochemical processes
of insulin signaling proceed via autophosphorylation of IR itself and its direct substrate
followed by activation of several pathways including the lipid kinase phosphor-inositidephosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and mammalian target of the
rapamycin signaling pathway (mTOR) eventually leading to carcinogenesis via abnormal
cells proliferation and inhibition of apoptosis [72]. Increased mitogenesis was also observed
in activated IRs in an insulin-resistant environment [73]. Due to the structural similarity
between IGF-R and IR (approximately 60% homology), insulin may also activate IGFR [73]. Activation of IR produces mainly metabolic effects, on the contrary activation of
IGF-R by insulin produces mitogenic effects including cell proliferation, angiogenesis, and
metastasis [67,74]. Studies have verified that restriction of calorie consumption leads to
reduced levels of insulin and IGF-1, complemented by declined insulin resistance and
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repressed mTOR pathway [75,76]. Furthermore, hyperinsulinemia stimulates an increase
of IGF-1 level through hepatic activation of growth hormone receptor (GHR), resulting
in increased secretion of growth hormone (GH) which stimulates IGF-1 [77]. An elevated
level of IGF-1 is considered a predisposing factor for premenopausal breast, prostate and
colorectal carcinogenesis [78]. Additionally, hyperinsulinemia also leads to a decreased
level of IGF-binding protein 1,2, and 3 resulting in an increased level of bioavailable IGF1 [67,79]. Elevated insulin level also minimizes liver production of sex-hormone-bindingprotein (SHBG) and shortage of this protein increases the level of bioavailable estrogen
or testosterone thus increasing the risk of hormone-dependent cancers [80]. Likewise,
hyperinsulinemia enhances the production of leptin (the mitogenic adipokine) by hypoxiainducible factor-1α (HIF-1α). Although the mitogenic effect of leptin was believed to
stimulate proliferation of esophagus, breast, and prostate cancer cells; it showed inhibitory
activity on pancreatic cancer cells [81].
4.2. Hyperglycemia
One of the notable characteristics of cancer cells is the increased uptake of glucose
and enhanced glucose metabolism [82] to be able to grow and divide rapidly. Cancer
cells possess altered metabolism via aerobic glycolysis, namely the “Warburg effect” [29].
Hyperglycemia promotes tumor growth via proliferation, anti-apoptosis, and metastatic
activity [83]. The proliferative effect induced by hyperglycemia occurs as a result of
overexpression of the following: glucose receptors (GLUT-1, GLUT-3) in tumor cells, protein kinase C (PKC-α), peroxisome proliferator-activated receptor (PPAR α and γ), and
epithelial growth factor (EGF) [83]. On the other hand, the anti-apoptotic activity of hyperglycemia is a consequence of the decreased level of prolyl hydroxylase (PDH) enzymes that
eliminate the hypoxia-inducible factor α (HIF-α), thus leading to elevated HIF-α, which is
a vital regulator of tumor cell survival in a hypoxic and anabolic environment. Additionally, hyperglycemia preserves cytochrome-c mediated apoptosis by elevated nicotinamide
adenine dinucleotide phosphate (NADPH). Hyperglycemia also promotes metastasis and
invasiveness due to several factors including epithelial to mesenchymal transition (ETM)
process, oxidative stress via reduction of reactive oxygen species (ROS) and increased
superoxide dismutase (SOD), and elevated expression of zinc transporters leading to enhanced zinc absorption which is involved in migration of cancer cells [84]. Moreover,
oxidative stress is a possible risk factor for carcinogenesis in diabetic people since it is the
initial mechanism of insulin resistance; which is due to the inactivation of insulin receptors
resulting from the overproduction of superoxide in the mitochondria [72].
In addition, increased glucose levels affect the epigenetic regulation resulting in
what is known as “hyperglycemic memory”; a condition that allows the activation of
oncogenic pathways in hyperglycemia-exposed tumor cells, even after constant glucose
level normalization [85]. Glucose-induced constant expression of NF-κB p65-gene is the
probable reason behind this mechanism [85]. Interestingly Jee et al. suggested that fasting
glucose level (FGL) > 125 mg/dL increases the risk of cancer incidence [86]. On the contrary,
a meta-analysis of major published trials clarified that the risk of cancer development was
not reduced in type 2 diabetics who followed an intensified glycemic control [87].
4.3. Chronic Inflammation Due to Fat Imbalanced Metabolism
Obesity promotes tumorigenesis according to evolving studies [88,89] stressing that
almost 80% of T2DM cases are associated with obesity and overweight [90]. Numerous
studies have also suggested that excess body adipose tissue is a risk factor for various
types of cancers, including breast, endometrial, esophageal, pancreatic, and colorectal,
cancers [88]. The tumor-promoting activity of obesity can be probably explained by
mechanisms such as alteration in sex hormones metabolism, changes in the levels of
adipokines, chronic inflammation, and insulin resistance [80,88]. Moreover, metabolic
and mitogenic variations induced by excessive adipose tissue enhance the impact of
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β1 (TGF-β1), which is essential in hepatic cell carcinogenesis. Studies have also proposed
that both T1DM and T2DM predispose to HCC, probably via hyperglycemia; in particular,
a slightly stronger correlation was noted with T1DM than that with T2DM [98]. On the
other hand, data from various studies have suggested that T2DM with its simultaneous
metabolic disorders activate oncogenesis in hepatic cells [99,100].
4.4.2. Prostate Cancer
Prostate cancer (PC) is the only described cancer in the literature associated with
DM [101]. Several studies reported the significant converse association between PC and
DM which suggested a protective effect of DM against PC [101–103]. Potential causes of
this association involve a low testosterone level (probably due to high glucose level) and
hypo-insulinemia observed in T1DM or T2DM in the long term. On the contrary, Li et al.
suggested that DM is associated with an improved risk of advanced PC development [104].
5. Impact of Diabetes and Obesity on Cancer
Obesity is a major public health concern around the world, and it is now considered a
crisis. It occurs as a result of changes in lifestyle (lack of physical activity, a high fat/calorie
diet, a high carbohydrate diet) and is often related to lifestyle factors such as cigarette
smoking and alcohol consumption. According to World Health Organization (WHO) over
1.9 billion people aged 18 and up were overweight in 2016. Over 650 million people were
overweight (body mass index ≥ 25 kg/m2 ) or obese (body mass index ≥ 30 kg/m2 ) [105].
Obesity and type 2 diabetes, “Diabesity is a new concept for diabetes that affects people
who are obese” have become much more common across the world, which are commonly
related to metabolic disorders and both are linked to a higher incidence and mortality
rate which can accelerate cancer progression [106]. Diabesity has been associated with
the development of pancreatic cancer and its pathogenesis in many studies [107]. In
addition, it contributes to an increased risk of a number of different cancers, including
breast, hematological and prostate cancer [108–110]. Diabesity has been related to cancer
progression through a number of mechanisms, including 1. insulin-like growth factor
signaling, activation of the insulin/IGF signaling pathway has been presumed to lead
to tumor initiation and/or progression just at the cellular level via tumor cell-specific
mechanisms such as cell division activation and glucose metabolism [111] and epithelialto-mesenchymal transition (EMT) [110] 2. Insulin resistance and hyperinsulinemia are
common in individuals with diabesity, C-peptide levels as indicators of insulin secretion
have been tested in many studies to see whether hyperinsulinemia is related to cancer
risk and mortality [112]. A 37% increased risk of colorectal cancer has been linked to
elevated C-peptide levels [113]. According to the Physicians Health Report, obese men
with increased C-peptide levels are likely to die from prostate cancer four times more than
men with normal C-peptide levels [114]. 3. Adipose tissue factors, adipose tissue is an
important organ for the production of adipokines, inflammatory cytokines, and enzymes
that are dysregulated in obesity and type 2 diabetes and potentially contribute to tumor
growth and metastases [106,107,110]. 4. Gut microbiome, Changes in the gut microbiota
have been linked to an increased risk of some cancers by inducing inflammatory responses
and leading to cancer proliferation [109]. Recognizing the link between adipose tissue
and tumors, the impact of obesity on immune cell function, and the effect of metabolic
health on cancer progression will be crucial for enhancing current therapy responses and
designing new therapies that address systemic metabolic.
6. Therapeutic Challenges in Treating Patients with Diabetes and Cancer
Various studies have indicated that cancer patients with diabetes have an inferior
prognosis in comparison to non-diabetic patients. This could be explained since diabetes
in cancer patients is a reason for higher infection rates, shorter remission periods, and
higher mortality rates [55,115–117]. Consequently, a variety of challenges face clinicians
when treating cancer patients with diabetes because of the cardiac, neurologic, and renal
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complications associated with diabetic patients. Chemotherapeutic choices and treatment
guidelines and, eventually, cancer outcomes could be affected due to the avoidance of
using some of the best clinical agents with the best survival rates in cancer patients since
these therapeutic agents may cause other disease complications [118].
6.1. Challenges Using Chemotherapeutic Agents
Cardiac, renal, and neuropathic complications usually develop in patients with
poorly controlled diabetes and these complications can also be caused or exacerbated
by many chemotherapeutic treatments. Anthracyclines, for example, may cause cardiotoxicity [119,120], and cisplatin could cause renal insufficiency. Consequently, the inability
to use cisplatin in testicular cancer therapy decreases the overall response rates and survival [121]. In addition, neurotoxicity, which is peripheral sensory neuropathy that occurs
approximately in (40–50%) of diabetic patients, mainly in the feet, may also be caused by
the use of cisplatin, vincristine, and paclitaxel; unfortunately, these side effects are usually
permanent [122,123]. Moreover, in order to achieve a successful cancer treatment, at least
85% of the chemotherapeutic dose should be given which necessitates careful monitoring
of patients with cancer and diabetes before starting and during chemotherapy. Treatment
of such patients must depend on the patient’s clinical picture since any alterations of
the patient’s dose, time of administration, or changing between chemotherapeutic agents
may affect the outcomes and lower the treatment response rate and also shorten patient’s
survival rates [117,124,125].
6.2. Challenges Using Glucocorticoids
Several cancer treatment protocols regularly use glucocorticoids either in high doses
for short-term therapy or in lower doses to alleviate nausea and vomiting that accompany
treatment with chemotherapeutic agents. Therefore, before starting glucocorticoid therapy
in any cancer patient, they should be tested for diabetes and also monitored closely after
that, mostly because these patients have a high chance of being undiagnosed since up to
a third of diabetic persons in the general public are undiagnosed [117]. The mechanism
of glucocorticoid action in raising blood glucose levels is by increased insulin resistance,
glycogenolysis, gluconeogenesis, and decreased insulin production and secretion [126].
Diagnosing cancer patients with diabetes during receiving glucocorticoid therapy is a
common phenomenon as well. In addition, the most important factors for glucocorticoidinduced diabetes are increased age, obesity, a family history of diabetes or a history of
gestational diabetes and treatment with high doses of steroids [127].
6.3. Challenges of Using Cancer Treatments While on Glucose-Lowering Treatments
Glucose-lowering treatments may influence cancer treatments and ultimately impact
cancer-specific mortality. A retrospective study was carried out by MD Anderson Cancer
Centre in order to determine whether treatment with metformin had affected the pathologic
complete response (pCR) rates in females with both diabetes and breast cancer on treatment
with neoadjuvant chemotherapy [128]. The study showed that the rate of pCR was 24% for
women on metformin treatment, 8.0% for women on therapy other than metformin, and
16% for non-diabetic women; those results highlight that many diabetic patients manifest a
weakened response rate to chemotherapy in comparison with non-diabetic patients. Furthermore, another two recently published studies affirmed similar results when metformin
was used by diabetic patients with colorectal cancer [129], and also patients with advanced
non-small-cell lung cancer undergoing first-line chemotherapy [130].
7. Suggested Therapies for Cancer and Diabetes Patients
It is essential to state that glucose may be a potentially relevant cancer mediator taking
into consideration the complexity of interactions between diabetes, diabetes treatments,
and cancer. The Warburg hypothesis emphasizes how many types of cancer depend on
glycolysis for energy, i.e., “glucose addiction” [29].
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One of the most effective diabetes management is to maintain improved control
over blood glucose, thus reducing the risks of developing the complications associated
with diabetes which leads to the minimization of morbidity and mortality rates. Therefore, regarding glucocorticoid therapy, rather than using a single bolus dose of steroids,
giving steroids intravenous over 24 h or multiple doses during the day can better help
control hyperglycemia in these patients. Diabetic patients treated with oral hypoglycemic
medications may be kept on their medications while carefully monitoring their glucose
levels. Nevertheless, in this case, these medications are usually inadequate for controlling
hyperglycemia. On the other hand, diabetic patients who are on insulin therapy before
starting the glucocorticoid therapy will usually need both basal and preprandial insulin
administration and would need to increase their usual dose(s) of insulin two to three times.
Moreover, in order to manage a patient’s induced or exacerbated hyperglycemia when using steroids, insulin is the preferred method in patients known with diabetes [126,127,131],
and insulin doses are determined depending on the patient’s weight. A faster way to
lower blood glucose levels is by intravenous insulin infusion which will also estimate
the total required daily insulin dose for insulin naïve patients. However, many hospitals do not allow the use of intravenous insulin drips unless it is used in intensive care
units due to the risk of hypoglycemia. Finally, insulin doses should be titrated daily
and should also be tapered whenever glucocorticoid therapy is tapered in order to avoid
hypoglycemia [126,127,131–134].
In addition, clinicians often need a flexible approach to diabetes management in cancer
patients because of the cyclical nature of chemotherapeutic agents, since platinum-based
chemotherapy (e.g., cisplatin), mTOR kinase inhibitors (e.g., everolimus), and ABL kinase
inhibitors (e.g., nilotinib) have all been connected to hyperglycemia.
Unfortunately, there are few published articles related to this area. However, from
the author’s experience, it is well known that diabetic patients with cancer need to be
monitored frequently for hyperglycemic during therapy, especially in cases of advanced or
incurable cancer patients undergoing palliative care [135].
8. Natural Products Targeting Diabetes and Cancer
8.1. Resveratrol
Resveratrol is a natural polyphenol that belongs to the class of stilbene [136]. It is derived from various plant types and is presented in 34 families containing 100 species [137].
In peanuts, soybeans, purple grapes and pomegranates, high resveratrol concentrations
have been found [138]. Resveratrol (3,5,40-trihydroxystilbene) is a stilbenoid and phytoalexin generated by a variety of plants as a result of injury or other pathogenic attacks [139]. Resveratrol has historically been used to treat stomach pain, hepatitis, arthritis,
urinary tract infections, and inflammatory and cardiovascular diseases [140]. Several
studies have recently reported the anticancer and antidiabetic effects of resveratrol.
Resveratrol demonstrated antiproliferative and apoptotic effects on human cervical
carcinoma cells by stimulating caspase-3 and caspase-9, impeding cell growth, inducing
p53 expression, and upregulating the X-associated protein Bcl-2 [141]. It prevented the
proliferation of colon cancer cells and induced cell apoptosis by suppressing the signaling
pathway of AKT/STAT3 [142]. It enhanced paclitaxel’s apoptotic and oxidant effects
by stimulating the TRPM2 channel in glioblastoma cells [143]. Additionally, it inhibited
pancreatic cancer cell metastasis by controlling the expressions of vimentin, CTA-2, IL-1β,
TNF- α, and N-cadherin [144]. Zhao et al. indicated that encapsulated resveratrol within
peptide liposomes decreased free resveratrol’s toxicity and enhanced the physicochemical
properties. It stimulated apoptosis in breast cancer by rising Bcl-2 activity, controlling
p53 and Bax expression, and inducing the activation of caspase-3 [145]. A combination of
thymoquinone and resveratrol was studied in both in vivo and in vitro models, and the
findings demonstrated substantial cancer cell inhibition, angiogenesis suppression, and
apoptosis elevation [146,147]. A synergistic effect between resveratrol and doxorubicin
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against breast cancer cells was observed. In Ehrlich ascetic carcinoma cells carrying mice,
combination therapy enhanced life span and decreased tumor volume [148].
Resveratrol was examined in mice by analyzing postprandial glucose concentrations
for its ability to inhibit α-glucosidase. The results showed that resveratrol delayed carbohydrate absorption, resulting in a reduced post-prandial blood glucose response [149]. Several
studies showed the antidiabetic effect of resveratrol [150]. Resveratrol was revealed to enhance muscle and liver glucose absorption, decrease adipose tissue and liver inflammation,
increase adaptive thermogenesis capability, and inhibit pancreatic insulin secretion [149].
Quercetin and resveratrol were considered to have positive effects on diabetes. A study
was conducted to investigate the combined antidiabetic action of quercetin and resveratrol
in diabetic rats induced by streptozotocin. Elevated serum blood glucose, insulin levels,
and dyslipidemia were significantly improved in diabetic rats by quercetin, resveratrol,
and combination therapies. These compounds inhibited oxidative stress and tissue injury
biomarkers substantially. Co-treatment of quercetin and resveratrol was useful against
diabetes as it maintained the hepatic glucose metabolic enzymes activities and structure of
pancreatic β-cells from the diabetes [151].
8.2. Curcumin
One of three components of phenolic difrauloylmethane compounds known as curcuminoids is curcumin. It is a major active ingredient found in Curcuma longa dried
rhizomes (family: Zingiberaceae), generally referred to as turmeric [152–154]. Curcumin
has several pharmacological properties such as anticancer, anti-diabetic, antioxidant, antiviral, antibacterial, anti-inflammatory, and wound-healing ability [152,154–157]. Curcumin
has been recognized as an anticancer agent via various mechanisms of action, including
cancer cell apoptosis activation, cancer cell metastasis suppression, and cancer cell growth
inhibition [155,158–160]. Curcumin has been identified in several signaling pathways such
as activation of apoptotic ligand-inducing tumor-necrosis-factor-related apoptosis (TRAIL)
pathways in HT-29 and HCT-116 colon cancer cells by upregulating death receptor factor
5 [161]. In HT-29 colon cancer, curcumin began Fas-mediated apoptotic pathway through
caspase 8 activation [162]. Bax expression was upregulated and Bcl-2 was inhibited via
phosphorylation at Ser15 and p53 activation in HT-29 colon adenocarcinoma cells [163],
and HCT-116 [155]. The anti-cancer effect of curcumin on osteosarcoma was reported
by inhibition of MG-63 cell proliferation and migration and inactivation of JAK/STAT
signal [164]. Curcumin was also useful against prostate cancer as it interfered with nuclear
factor κ (NFκB), epidermal growth factor receptor (EGFR), and mitogen-activated protein
kinase (MAPK) [165].
A study revealed that 14 days treatment of human adipocytes with turmeric ethanol extract, containing curcumin, demethoxycurcumin, bisdemethoxycurcumin and ar-turmerone,
led to improved adipocyte differentiation substantially in a dose-dependent manner, increase glucose elevation levels and enhance the activity of human peroxisome proliferatoractivated receptor (PPAR)-gamma ligand-binding [166]. Furthermore, treatment of 3T3-L1
adipocytes with curcumin decreased glucose uptake, leptin levels, NF-kB p65 nuclear fraction, phospho-JNK1/2, phospho-IRS-1(S), MMP-2, MMP-9 and VEGF protein. However, it
elevated insulin sensitivity, adiponectin levels, and IRS-2 protein [166].
Curcumin supplementation greatly stopped the progression and disruption of the
renal lesion. It decreased the levels of urinary enzymes (acid phosphatase, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)).
Additionally, it decreased lactate dehydrogenase and renal glucose-6-phosphatase and
increased ATPase activity [167]. The co-administration of curcumin and metformin reduced JAK/STAT signalling pathway expression substantially to suppress myocardial
degeneration and diminish lipid peroxidation levels, IL-6, creatine kinase-MB (CK-MB),
troponin I, and tumor growth factor-β1 (TGF-β1) [168].
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8.3. Thymoquinone
The major phytochemical bioactive constituent identified in volatile oil isolated from
Nigella sativa (black cumin, black seed) is thymoquinone, which has been used in several countries as a traditional medicine [146,169,170]. Thymoquinone has antihistaminic,
immunomodulatory, antioxidant, antitumor, anti-inflammatory, and antimicrobial activities [170–174].
Thymoquinone can be used as an anticancer agent as it can alter the regulation of cell
cycle, growth factor, apoptosis, tumor-suppressor gene, protein kinase enzyme, transcription factors, survival signals, and phase I and II enzymes [170]. Altering the progression of
the cell cycle is an essential step in inhibiting the development and progression of cancer.
Fatty acid-conjugated thymoquinone has a promising effect on apoptosis, cell proliferation,
and signaling pathways [170]. In the human mammary breast cancer epithelial cell line,
MCF-7, thymoquinone induced cell arrest at various stages according to the concentration
used (25 and 50 µM) in vivo [175]. Furthermore, it was used to reduce serum TNF- α,
IL-6, and iNOS enzyme production and improve histopathological outputs in Wistar rats
with methotrexate-induced hepatorenal system injury [176]. It played an important role
in suppressing endothelial cell migration and tumor angiogenesis. In HCT 116 human
colon cancer cells, thymoquinone significantly reduced the phosphorylation of EGFR to
tyrosine-1173 residues and JAK2 in vitro [177]. It has an antiproliferative effect, particularly
when combined with doxorubicin and 5-fluorouracil, resulting in increased cytotoxicity
in the xenograft mouse model of breast cancer [178]. A study showed that thymoquinone
activates apoptosis by reducing antiapoptotic protein expression [179].
Thymoquinone has antidiabetic and antioxidant activities. It can reduce blood glucose
level, triglycerides and cholesterol concentrations. On the other hand, it can improve the
high-density lipoprotein, insulin sensitivity, and pancreatic β-cell regeneration resulting
in substantial enhancement of the oral glucose tolerance test [180]. Glycolysis and Kreb’s
cycle pathways were used by thymoquinone to enhance glucose utilization while gluconeogenesis was used to decrease glucose production [181]. Thymoquinone enhanced the
antidiabetic effect of metformin [182]. It can maintain the integrity of pancreatic β-cells
by enhancing oxidative stress which subsequently raises the level of insulin [181]. Nigella
sativa consumption can reduce inflammatory and oxidative stress markers [183]. Serum
high-sensitivity C-reactive protein, tumor necrosis factor-α, and malondialdehyde levels
were significantly reduced by Nigella sativa intake, while total antioxidant ability and
superoxide dismutase levels were significantly increased [183].
8.4. EGCG (Epigallocatechin Gallate)
The natural polyphenol that belongs to the class of flavonols is epigallocatechin-3gallate (EGCG) [184]. Green tea (Camellia sinensis, Theaceae) [185] and cocoa products [186]
are the major dietary sources of EGCG. Green tea was utilized in the past as a diuretic,
astringent, stimulant, and to improve heart health in Indian and Chines medicine [187].
EGCG has numerous medical benefits, including suppression of tumor growth, inhibition
of irregular blood clot formation, and reduction of LDL cholesterol levels [188]. EGCG is
the most effective anti-inflammatory and anticancer agent among the various green tea
catechin derivatives [189].
EGCG can be utilized as an anticancer agent as it has antimetastasis, antiproliferative, and pro-apoptosis activities. The antimetastasis activity of EGCG was mediated
by suppression of MMP-2 protein expression through modulation of the Src signaling
pathway [190]. The synergistic chemotherapeutic potential was demonstrated by the combination of EGCG with eugenol or amarogentin in the cervical cancer cell line [191]. The
antiproliferative effect of EGCG was proved by its capability to suppress cyclinD1 and
improve LIMD1, RBSP3, and p16 cell-cycle inhibitors at the G1/S cell cycle level [192].
Moreover, by reducing multi-drug resistance 1 signaling and stimulating the AKT/STAT3
pathway, EGCG was capable to alert cisplatin-resistant oral cancer CAR cell apoptosis
and autophagy [193]. The effect of EGCG on doxorubicin-induced cytotoxicity of oral
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keratinocytes and anticancer activity against oral cancer cells was reported. It reduced the
doxorubicin cytotoxic effect without impairing its anticancer efficacy [194].
EGCG has an antidiabetic effect. In a reversible and non-competitive way, EGCG inhibited α-glucosidase because of the complex formation between EGCG and α-glucosidase,
where the hydrogen bonds played an important role, EGCG quenched α-glucosidase fluorescence. EGCG strongly affected the secondary structure and the microenvironment of
α-glucosidase. Furthermore, EGCG increased the glucose uptake and stimulated GLUT4
translocation to the plasma membrane through PI3K/AKT signaling pathway in L6 skeletal
muscle cells [195].
EGCG also has an antiobesity effect. Green tea supplementation can help obese
patients lose weight and lower their body mass index by several mechanisms, including
inhibition of ghrelin secretion and adipogenesis, improvement of adiponectin levels, and
reduction of nutrient absorption [196].
8.5. Allicin
Allicin is a sulfenic acid thioester, or allyl thiosulfinate. It is predominantly present in
garlic (Allium sativum) and belongs to the family Liliacerae [197]. Allicin has various biological activities, including anticancer, antidiabetic, antimicrobial, and anti-inflammatory
activity. Allicin substantially inhibited cholangiocarcinoma cell invasion and cell proliferation. It prohibited cell migration and prompted apoptosis via upregulation of SHP-1
and inhibition of the activation of STAT3 [198]. A study showed that allicin improved the
X-ray radiotherapy sensitivity in colorectal cancer by inhibiting the signaling pathway
of NF-κ [199]. Furthermore, allicin demonstrated anti-tumor activity against HCMVinfected glioma cells through cytokine release downregulation, p53 activity stimulation,
and radiotherapy sensitivity enhancement [200]. Another study revealed allicin activity
in stimulating apoptosis of cells and in suppressing ornithine decarboxylase which is a
rate-limiting enzyme in neuroblastoma cell proliferation [201]. By increasing cyclin D1 and
reducing MMP-9 mRNA expression, allicin inhibited melanoma cell growth [202]. Allicin
also has synergistic anticancer activity against colorectal and lung carcinoma cells with
5-fluorouracil [203].
Allicin has antidiabetic activities. It was helpful in the treatment of diabetic nephropathy [204]. It enhanced insulin levels, reduced hyperglycemia, and prohibited changes in
(GLUT4) and IRSs expression induced by diabetes [204]. It also increased the expression of
Nrf2 and decreased the expression of Keap1, HIF-1α, SBP, and VEGF [204]. Treatment with
allicin successfully decreased autoantibodies and anti-islet cell antibodies (ICA) for type 1
diabetes (IDDM). As a result, pancreatic tissues were restored and the decreased serum
insulin level was greatly increased [205].
8.6. Emodin
Emodin is most widely isolated from the Rheum palmatum (Chinese rhubarb, family:
Polygonaceae) roots and rhizomes. It is also existed in Polygonum multiflorum (Chinese
knotweed), Polygonum cuspidatum (Asian knotweed), Cassia obtusifolia (Chinese senna,
family: Fabaceae), Aloe vera (family: Asphodelaceae), Aspergillus wentii, and Aspergillus
ochraceus [206–209]. Emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) is a natural derivative of anthraquinone [210]. It has different Pharmacological activities, including antitumor,
antimetastatic, antiproliferative, antidiabetic, antiviral, antibacterial, anti-inflammatory,
and immunosuppressive activity [211–214]. Emodin’s molecular mechanisms are apoptosis,
cell cycle arrest, and expression promotion of the detoxification enzymes hypoxia-inducible
factor 1α, glutathione phase I and II, and glutathione S-transferase P,N-acetyltransferase.
Emodin can also inhibit angiogenesis, invasion, migration, and formation of chemicalinduced carcinogen-DNA adducts, HER2/neu, CKII kinase, and p34cdc2 kinase human
cancer cells [215]. Tumor-associated angiogenesis was inhibited via the reduction of
ERK phosphorylation.
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Emodin has an important role in the treatment of diabetic nephropathy. It can reduce
hyperglycaemia and stimulate cell proliferation and fibronectin expression by preventing
cellular FLICE-inhibitory protein (cFLIP) and p38MAPK pathway. Additionally, it has a
PPARγ-activating effect. It improved the symptoms of diabetic animals through PPARγ
pathway regulation. Furthermore, glycolysis was improved by emodin through the AMPK
signalling pathway [216].
8.7. Genistein
Genistein [40,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl) chromen4-one] is an isoflavonoid derivative and it belongs to phytoestrogen classes. It exists in
glycosylated or free forms in food (mainly legumes). It was firstly isolated from Genista
tinctoria. It was also found in lycine max (Soybean), soy-based foods, soy-based drinks,
Lupin (Lupinus perennis), broad beans and chick peas. Genistein has pharmacological activities, including anticancer, antidiabetic, antiosteoporetic, and estrogenic activity [217,218].
The mechanisms of genistein as anticancer agent include reducing proliferation, preventing angiogenesis and metastasis, and stimulating apoptosis [219,220]. Genistein has a
good inhibitory effect against various cancer cell lines, including melanoma (MML-1 and
SK-MEL-2), breast carcinoma (MDA-MB-231 and T47D), pancreas carcinoma (BxPC-3
and PANC-1), colon carcinoma (HT29 and COLO201), glioblastoma (U87 and LN229),
and lung carcinoma (A549 and NCI-H460) [221]. Genistein was documented to inhibit
cyclooxygenase-2 (COX-2) directly and indirectly by suppressing COX-2-stimulating factors such as activated protein-1 (AP-1) and Nf-κB. In pancreatic, colon, breast, and lung
cancers, COX-2 overexpression was recognized and its inhibition was associated with
decreased cancerous tumor growth in the esophagus and colon [217].
A study stated that genistein has anti-inflammatory and antidiabetic functions, especially direct effects on the proliferation of β-cells and the secretion of insulin. Genistein
improved glucose homeostasis [222]. In β-cells, phytonutrient genistein easily stimulated
cAMP signaling. It also improved the mass of islets in diabetic mice. CAMP generation
genistein stimulation was eliminated in islets exposed to G15 unique GPR30 inhibitor or
GPR30 deficient islets (GPR30−/−) mice [223].
8.8. Parthenolide
In the Asterceae family of medicinal plants, especially in Tanacetum parthenium (feverfew) [224], parthenolide is an essential naturally occurring metabolite [225]. It can also
be found in Tanacetum vulgare (tansy) and Tanacetum larvatum [226]. Parthenolide was
traditionally utilized to treat rheumatoid arthritis, fever, and migraine, while lately, it
has been shown to have anticancer effects in various types of cancer, including bladder
cancer, breast cancer, cholangiocarcinoma, pancreatic cancer, leukemia, prostate cancer, and
cholangiocarcinoma [227]. Parthenolide’s anticancer mechanisms include DNA replication
inhibition [216], STAT3 inhibition, apoptotic pathway stimulation [217], p.53 activation,
and upregulation the production of reactive oxygen species (ROS) [228]. A study reported
that parthenolide directly affected malignant cells without affecting normal cells [229].
Parthenolide was effective against distinct cholangiocarcinoma cell lines [230], because
it induced apoptosis. Parthenolide inhibited breast cancer stem-like cells by stimulating
oxidative stress and necrosis [231]. Furthermore, the growth of transplanted glioblastoma cells was significantly inhibited by parthenolide [232]. In pancreatic cancer cells,
parthenolide can improve gemcitabine’s antiproliferative effects [233].
Parthenolide can reduce inflammation and remodel the impaired insulin signaling
pathway, allowing cubilin and albumin uptake to be expressed [234]. During adipogenesis,
adipogenic factors and lipid accumulation were reduced by parthenolide. In a dosedependent manner, parthenolide inhibited adipogenic factors (PPARc and C/EBPa) and
its target protein FABP4 production [235]. The regulation of reactive oxygen species
production by parthenolide was linked to the control of the Nrf2-(Keap1) pathway [235].
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8.9. Luteolin
Luteolin is a natural flavonoid abundantly present in many plant species. It is mainly
found in vegetables and fruits, such as sweet bell peppers, carrots, onion leaves, broccoli,
parsley, chrysanthemum flowers, and celery [236,237]. It was isolated from Platycodon grandiflorum, Perilla frutescens, Apium graveolens, Cajanus cajan, Apium graveolens, Mentha spicata,
and Sesbania grandifolra [238]. Luteolin was utilized in the treatment of prostate, breast, pancreatic, skin, colon, oral, lung, ovarian, and kidney cancers [239]. It has a potent cytotoxic
effect against different breast cancer cell lines, including MDA-MB-231 and BT5-49 [239]. It
obstructed cell proliferation and stimulated apoptosis of H460 and A549 cells [240–242]. It
inhibited metastasis, angiogenesis, and cell proliferation, and stimulated apoptosis through
various mechanisms [243]. The extrinsic and intrinsic apoptosis pathways were stimulated
and the death receptor 5 expression was improved by luteolin [244]. Stimulating JNK
and obstructing translocation of NF-κB were mediated the cellular growth inhibition, G2
arrest, and apoptotic cell death induction [245]. Furthermore, luteolin inhibited cancer cell
proliferation by angiogenesis inhibition via blocking VEGF receptor stimulation and its
downstream molecule PI3K/Akt and PI3K/p70S6 kinase pathways [246].
Colon cancer and diabetes are the primary cause of death worldwide [247]. Various
luteolin signaling pathways, including SOD, p53, eNOS, Wnt, iNOS, MMP9, and the
cyclin-CDK pathway, are used to treat cancer/diabetes [247]. Since chronic hyperglycemia
produces an intracellular level of reactive oxygen species, luteolin has anti-diabetic activity
due to its antioxidant properties [247]. Moreover, luteolin can regulate diabetes through
mammalian targets of rapamycin (mTOR), cytokine, AMPK, and p53 [247].
8.10. Quercetin
Quercetin is a polyphenolic flavonoid found in apples, berries, broccoli, onions,
broccoli, green tea, red tea [248], Aesculus hippocastanum, Ginkgo biloba, and Hypericum
perforatum [249]. The biological activities of quercetin are anticancer, antidiabetic, antiobesity, neuroprotective, antimicrobial, antiviral, hepatoprotective, and anti-inflammatory
activity [250]. Quercetin stimulated apoptosis and inhibited cellular growth through the reduction of epidermal growth factor receptor (EGFR) expression [251]. It induced apoptosis
by directly upregulating caspase-3 and-9 and proapoptotic Bcl-2 family members, but it
also induced apoptosis by directly downregulating antiapoptotic Bcl-xL [252]. Moreover, it
possessed a cytotoxic effect against different breast cancer cell lines, including MDA-MB231 and MCF-7 via apoptosis activation along with G1 phase arrest [253,254]. Quercetin
improved the chemosensitivity of breast cancer cells to doxorubicin by obstructing proliferation and invasion of cells, leading to apoptosis activation [255]. It also has good cytotoxic
effects against human lung carcinoma A549 cells as it can inhibit cell invasion and migration, stimulate apoptosis, and decrease the number of tumor cells [256]. A study showed
that 16 weeks of administration of quercetin at a concentration of 200 and 400 mg/kg can
decrease the number and the tumor size of papillomas in skin tumors prompted by croton
oil in Swiss albino mice [257].
Quercetin can decrease serum glucose level through several mechanisms, including
antioxidant action, modulating hepatic gene expressions, obstructing α-glucosidase activity
in vitro, and improving insulin action along with skeletal muscle mitochondrial biogenesis
enhancement [258]. It was utilized to reduce blood glucose and urine sugar levels, and
increase plasma insulin and hemoglobin levels [259]. Quercetin was found to be an effective
PPAR-γ inhibitor [259].
8.11. Berberine
Berberine isolated from Coptis japonica Makino, Coptis chinensis Franch, and Berberis
aristata Sims is an essential isoquinoline alkaloid. It is found in barberry, goldenseal, tree
turmeric, and oregon grape [260]. It is a pharmacologically significant secondary metabolite
as it can help in the treatment of cancer, diabetes, and obesity [260].
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Colorectal, lung, liver, ovarian, prostate and cervical cancers are all inhibited by
berberine [260]. Under illumination with a black light lamp (320,450 nm; 20 W), SGC803
gastric cancer cells combined with berberine (10 g/mL) showed a good inhibitory proliferation effect. Additionally, berberine combined with 5-ALA-photodynamic therapy inhibits
MGC-803 gastric cancer cell proliferation, reduces survivin and Bcl2 expression, stimulates
cell apoptosis, and upregulates p53 and Bax expression. These findings imply that berberine has the ability to be utilized in conjunction with photosensitizers [260]. Activating
apoptosis and autophagy, inhibiting cell proliferation, and altering protein expression are
berberine-photodynamic therapy’s mechanisms in treating tumors [260]. Furthermore,
berberine was utilized against breast cancer as it improved JNK phosphorylation, activated
caspase-3, reduced the mitochondrial membrane potential, decreased the expression of
Bcl-2, and increased the release of cytochrome c and AIF [261].
Berberine decreased blood glucose and the risk of metabolic syndrome, improved
insulin sensitivity, stimulated weight loss, improved lipid metabolism, reduced the levels
of hemoglobin A1C and triglyceride, increased the mRNA expression of adiponectin, and
reduced leptin and resistin secretion [262]. Reduction of body weight, body mass index,
and waist circumference was revealed after the administration of 500 mg of berberine either
two or three times a day for three months [262].
8.12. Phytosterols
Phytosterols are plant-derived lipid compounds that are similar to cholesterol but
differ in their carbon side chains and the presence or absence of a double bond. They
are divided into two categories which are sterols (unsaturated compounds) and stanols
(saturated molecules) [263]. Phytosterols are commonly found in plants or macro fungi
and have a number of pharmacological activities, including anticancer, hypolipidaemic,
anti-inflammatory, and antidiabetic activity [263].
Phytosterols can be utilized to improve breast, ovary, liver, lung, prostate and stomach
cancers. They have several suggested mechanisms, including inhibition of carcinogen
production, angiogenesis, cancer cell growth, multiplication, invasion, and metastasis and
induction of apoptosis and cell cycle arrest [264]. Female SCID mice were fed specified
diets supplemented with 2% phytosterols, 2% cholesterol, or a 0.2% cholic acid vehicle
to evaluate the effects of phytosterols on breast cancer cell growth and metastasis [264].
After 2 weeks, mice were injected with MDA-MB-231 cells into their inguinal mammary fat
pads. Eight weeks after the dietary supplementation, mice given phytosterols had a 40%
reduction in serum cholesterol levels [264]. Tumor sizes were 33% lower in animals fed the
phytosterol diet compared to those fed the cholesterol diet [264]. Tumor cell metastasis to
lymph nodes and lungs was 57% of the phytosterol-fed animals and 71% of the cholesterolfed animals [264]. Another study showed that β-sitosterol enriched diet decreased tumor
size in ovariectomized athymic mice injected with MCF-7 cells by 32–42% [264].
Phytosterols have been shown to substantially lower total cholesterol (TC) and lowdensity lipoprotein cholesterol (LDL-C) in the blood, and rise the HDL-C/LDL-C and
HDL-C/TC indexes [265]. Ergosterol could be a promising hypoglycemic agent for the
treatment of type 2 diabetes, with a mechanism of stimulating GLUT4 translocation and
expression through the PI3K/Akt and PKC pathways [265]. Ergosterol was utilized to
improve insulin resistance and blood lipid indices, and decrease fasting blood glucose
levels. Furthermore, the phosphorylation of Akt and PKC was improved in different
tissues [265]. Table 2 summarizes the anticancer and antidiabetic mechanisms for selected
natural products that target both diseases.
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Table 2. Antidiabetic and anticancer activity of some natural products that have the ability to treat both diseases.
Natural Products

Resveratrol

Curcumin

Thymoquinone

EGCG

Mechanism of Action in Cancer

Mechanism of Action in Diabetes

↑ caspase-3 and caspase-9, p53, X-associated
protein Bcl-2 in human cervical carcinoma [141]
↓ signaling pathway of AKT/STAT3 in colon
cancer cells [142]
↑ TRPM2 channel in glioblastoma cells [143]
control the expressions of vimentin, CTA-2,
IL-1β, TNF- α, and N-cadherin in pancreatic
cancer cells [144]
↑ Bcl-2 activity, p53, Bax, and caspase expression
in breast cancer [145]
↓ tumor volume in Ehrlich ascites carcinoma
cells [148]

↓ α-glucosidase, carbohydrate absorption, and
post-prandial blood glucose response in
mice [149]
↑ muscle and liver glucose absorption
↓ adipose tissue and liver inflammation
↑ adaptive thermogenesis capability
↓ pancreatic insulin secretion, and mimic caloric
restriction effects [149]
↑ serum blood glucose, insulin level, and
dyslipidemia in diabetic rats [151]

↑ apoptotic ligand-inducing
tumor-necrosis-factor-related apoptosis (TRAIL)
pathways
↑ death receptor factor 5in HT-29 and HCT-116
colon cancer cells [161]
↑ Fas-mediated apoptotic pathway, caspase 8
activation, Bax expression
↓ Bcl-2 in HT-29 colon cancer [162,163], and
HCT-116 [155]
↓ JAK/STAT signal in osteosarcoma [164]
interfere with nuclear factor κ (NFκB), epidermal
growth factor receptor (EGFR), and
mitogen-activated protein kinase (MAPK) in
prostate cancer [165]

↑ adipocyte differentiation substantially, glucose
levels, and the activity of human peroxisome
proliferator-activated receptor (PPAR)-gamma
ligand-binding [166]
↓ glucose uptake, leptin levels, NF-kB p65
nuclear fraction, phospho-JNK1/2,
phospho-IRS-1(S), MMP-2, MMP-9 and VEGF
protein in 3T3-L1 adipocytes [166]
↓ levels of urinary enzymes (acid phosphatase,
alkaline phosphatase (ALP), aspartate
aminotransferase (AST), and alanine
aminotransferase (ALT)) [167]
↓ JAK/STAT signalling pathway
↓ myocardial degeneration, lipid peroxidation
levels, IL-6, creatine kinase-MB (CK-MB),
troponin I, and tumor growth factor-β1 (TGF-β1)
in co-treatment with metformin [168]

↓ cell arrest at various stages in MCF-7 cell
line [175]
↓ serum TNF- α, IL-6, and iNOS enzyme
production and improve histopathological
outputs in Wistar rats [176]
↓ phosphorylation of EGFR to tyrosine-1173
residues and JAK2 in HCT 116 [177]
↑ cytotoxicity in the xenograft mouse model of
breast cancer [178]
↑ apoptosis by reducing antiapoptotic protein
expression [179]

↓ blood glucose level, triglycerides and
cholesterol concentrations
↑ high-density lipoprotein, insulin sensitivity
and pancreatic β-cell regeneration [180]
maintain the integrity of pancreatic β-cells by
enhancing oxidative stress [181]

↓ MMP-2 through modulation the Src signaling
pathway in cervical cancer [190]
↓ cyclinD1
↑ LIMD1, RBSP3, and p16 cell-cycle inhibitors at
the G1/S cell cycle level in cervical cancer cell
line [192]
↑ AKT/STAT3 pathway, apoptosis in
cisplatin-resistant oral cancer cell [193]

↓ α-glucosidase
↑ glucose uptake
↑ GLUT4 translocation to plasma membrane
through PI3K/AKT signaling pathway in L6
skeletal muscle cells [195]
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Table 2. Cont.
Natural Products

Mechanism of Action in Cancer

Mechanism of Action in Diabetes

Allicin

↓ cell migration, STAT3
↑ SHP-1, apoptosis in cholangiocarcinoma
cell [198]
↓ signaling pathway of NF-κ in colorectal
cancer [199]
↓ cytokine release
↑ p53 and radiotherapy sensitivity enhancement
in glioma cells [200]
↑ apoptosis
↓ ornithine decarboxylase in neuroblastoma
Cells. [201]
↓ MMP-9 mRNA expression
↑ cyclin D1 in melanoma cells [202]

↑ insulin levels
↓ hyperglycemia, (GLUT4) and IRSs
expression [204]
↑ Nrf2
↓ Keap1, HIF-1α, SBP, and VEGF [204]
↓ autoantibodies and anti-islet cell antibodies
(ICA) for type 1 diabetes (IDDM) [205]

Emodin

↑ apoptosis, cell cycle arrest, HIF-1α, glutathione
phase I and II, and glutathione S-transferase P,
N-acetyltransferase
↓ angiogenesis, invasion, migration, formation of
chemical-induced carcinogen-DNA adducts,
HER2/neu, CKII kinase, and p34cdc2 kinase in
human cancer cells [215]
↓ ERK phosphorylation in epithelial ovarian
cancer [266]

↓ cellular FLICE-inhibitory protein (cFLIP) and
p38MAPK pathway
↑ activate PPARγ pathway, and modulate AMPK
signalling pathway [216]

Genistein

↓ proliferation, angiogenesis and metastasis
↑ apoptosis leading to tumor growth reduction
in hepatocellular and gastric cancer models of
Wistar rats [219,220]
↓ COX-2-stimulating factors such as activated
protein-1 (AP-1) and Nf-κB in pancreatic, colon,
breast, and lung cancer [217]

modulate the proliferation of β-cells and the
secretion of insulin [222]
↑ cAMP signaling, and the mass of islets in
diabetic mice [223]

interrupt DNA replication [267]
↓ STAT3
↑ apoptotic pathway [268]
↑ p53 and reactive oxygen species (ROS) [228]
↓ breast cancer stem-like cells by stimulating
oxidative stress and necrosis [231]
↓ cell growth of glioblastoma cells [232]

↓ inflammation and remodel the impaired
insulin signaling pathway
↑ cubilin and albumin uptake expression [234]
modulate reactive oxygen species production,
and control the Nrf2- (Keap1) pathway [235]
↓ adipogenic factors (PPARc and C/EBPa) and
its target protein FABP4 production [235]

↑ apoptosis pathways and death receptor 5
expression [244]
↑ JNK
↓ NF-κB, mediate the cellular growth inhibition
and G2 arrest [245]
↓ proliferation, angiogenesis, VEGF receptor,
PI3K/Akt and PI3K/p70S6 kinase
pathways [246]
↓ cell proliferation and stimulate apoptosis in
H460 and A549 cells [240–242]

regulate diabetes through mammalian target of
rapamycin (mTOR), cytokine, AMPK, and
p53 [247]

↑ apoptosis
↓epidermal growth factor receptor (EGFR)
expression [251]
↑ caspase-3 and-9
↓ Bcl-2, Bcl-xL [252]
↑ G1 phase arrest in breast cancer cell
lines [253,254]
↓ cell invasion and migration
↑ apoptosis in human lung carcinoma A549
cells [256]

↓ serum glucose level
modulate hepatic gene expressions
↓ α-glucosidase activity, and PPAR-γ
↑ insulin action [259]

Parthenolide

Luteolin

Quercetin
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Table 2. Cont.
Natural Products

Berberine

Phytosterols

Mechanism of Action in Cancer

Mechanism of Action in Diabetes

↓ survivin and Bcl2
↑ apoptosis, p53, and Bax expression in gastric
cancer cells [260]
↑ JNK phosphorylation, cytochrome c and AIF,
and caspase-3
↓ mitochondrial membrane potential, and Bcl-2
expression in breast cancer [261]

↓ blood glucose
↓ risk of metabolic syndrome, levels of
hemoglobin A1C and triglyceride
↓ leptin and resistin secretion
↑ insulin sensitivity and weight loss
↑ lipid metabolism and mRNA expression of
adiponectin [262]

↓ cell growth and metastasis
↓ tumor size in athymic mice injected with
MCF-7 cells [264]

↑ GLUT4 translocation
↑ PI3K/Akt and PKC pathways
↓ fasting blood glucose levels [265]

9. The Controversy of Exogenous Antioxidants Administration in Cancer
Research and studies about the role of reactive oxygen species (ROS) and the effect
of exogenous administration of antioxidants’ supplements in cancer are opposed with
controversy and conflicting outcomes. On one hand, antioxidants are commonly used by
cancer patients and healthy individuals as a cancer-fighting strategy [269–271]. Clinical
trials with antioxidants, on the other hand, have shown contradictory findings; some trials
showed that antioxidants raised cancer risks [272–275].
Klein A et al. conducted a study between 2004 and 2011 and found that prostate cancer
risk for healthy men was markedly increased upon supplementation with 400 IU/day
of vitamin E supplement [276], whereas VI Sayin et al. clarified that supplementation
with the antioxidants N-acetylcysteine (NAC) and vitamin E noticeably enhances human
lung cancer cells proliferation and tumor progression in mice with B-RAF- and K-RASinduced lung cancer via decreasing ROS, DNA damage, and p53 levels. Additionally,
Volkan S. et al. showed that the antioxidants supplementation may accelerate early tumors
or precancerous lesions growth in elevated-risk populations (like smokers and chronic
obstructive pulmonary disease patients who receive NAC to reduce mucus production)
because the somatic p53 mutations occur late in the tumor progression process [277].
Another study by Clotilde W. et al. demonstrated that long-term supplementation of NAC
and vitamin E stimulates K-RAS-induced lung cancer metastasis by decreasing free heme
levels and stabilizing the pro-metastatic basic leucine zipper transcription factor 1 (BACH1).
BACH1 stimulates glycolysis-dependent metastasis of mouse and human lung cancer cells
by activating transcription of Hexokinase 2 and Gapdh and increasing glucose uptake,
glycolysis rates, and lactate secretion [278]. Moreover, Le Gal et al. studied the effect of
antioxidants on malignant melanoma in a mouse model and showed that the administration
of NAC and Trolox (the soluble vitamin E analog) expand lymph node metastases and
cause increased glutathione-synthesis-dependent invasiveness [279]. Indicating that active
tumors preserve ROS levels within limits that stimulate proliferation without leading to
cytotoxicity [280]. Similar results of melanoma metastasis were found in a different mouse
model (NOD-SCID Il2rg−/− (NSG) mice) when supplemented regularly with subcutaneous
injection of NAC [281]. Clinical trials involving the use of antioxidants combined with
chemotherapy are summarized in Table 3.
In conclusion, the supplementation of exogenous antioxidants may aid cancer cells
to navigate the metastatic cascade and adopt adaptive steps to counteract the beneficial
effect of antioxidant supplements. Nevertheless; additional clinical studies are required to
confirm the generalizability of these remarks and to expand them to practical application
especially with existing cancer patients.
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Table 3. Clinical trials conducted using combination treatment of antioxidants with chemotherapeutic agents.
Combination Treatment

Results

Ref.

Vitamin C + doxorubicin

Increased resistance to treatment in cell lines of chronic
myelogenous leukemia (K562) and lymphoma (RL)

[282]

Larger tumors in mice with RL cell xenografts
Resveratrol + paclitaxel

Decreased antitumor action of paclitaxel in human breast
tumor cells

[283]

Quercetin at low doses + cisplatin, 5-FU, taxol
or pirarubicin

Decreased efficiency of the treatment in athymic nude mice
with ovarian tumor cells (C13*) xenografts

[284]

N-acetylcysteine before or up to 1 h after the
drug + cisplatin

Blockade of proapoptotic effect of cisplatin in human
ovarian carcinoma cells (SKOV3), human SCLC tumor cells
(B.5 LX-1), human glioblastoma cells (U87), and
rat fibroblasts

[285]

10. Conclusions
Cancer and diabetes represent global health challenges and the number of patients
is contentiously increasing for both diseases. Hyperglycemia, hyperinsulinemia, and
imbalanced fat metabolism in diabetic patients increase the altered metabolism in cancer
cells. This metabolic link between cancer and diabetes complicates therapeutic protocols
and reduces survival rates. Natural products with their diverse mechanisms of action can
be used as adjuvant therapy to enhance conventional treatments. These natural products
act by targeting interconnected mechanisms between cancer and diabetes. Further research
is needed to explore the potential use of natural products in combination therapies to treat
cancer in diabetic patients.
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